Retatrutide first dose: the first four weeks in the trials
Reviewed 14 sourcesPublished by PepVault
Retatrutide's first dose in its trials: the 2 mg start, how long one shot lasts, when appetite and stomach effects showed up, and the first-shot routine.

- Last reviewed
- Sources
- 14
- Questions
- 7
- Compounds
- 2
The short answer
In retatrutide's phase 3 trials the first shot was 2 mg once weekly, kept for four weeks before the first step-up. Appetite changed early: 31 of 36 phase 2 participants interviewed said their eating changed within eight weeks. Stomach effects came mainly in the step-up weeks and were lower from a 2 mg start than a 4 mg one. Retatrutide is investigational, so these are trial schedules, not a dose.
Evidence: Randomised phase 1, phase 2 and phase 3 trials in people, published in The Lancet, NEJM, Cell Metabolism and Nature Medicine, plus phase 2 interview and questionnaire studies and Lilly's releases; retatrutide is investigational, and the injection routine follows the approved tirzepatide (Zepbound) label.

What was the first dose in the retatrutide trials?
Every retatrutide arm of the phase 3 obesity trials, TRIUMPH-1 and TRIUMPH-2, opened at 2 mg once weekly and stayed there for four weeks before the first step-up; the 4 mg arm took only that one step113. The design paper calls it a fixed dose escalation regimen: a 16-week escalation period, then the assigned dose for the rest of the 80 weeks, with neither participants nor staff told who was assigned which dose14.
Phase 2 tested the opening itself. In the obesity trial, the same target dose was reached from a 2 mg start in some arms and a 4 mg start in others3, and the trial's results record states why the climb was there: to improve stomach tolerability4. The full ladder after the first month, and every arm the trials ran, is in PepVault's guide to retatrutide dosage in trials.
These are the schedules trial clinicians set and monitored for an investigational drug. They describe what was studied, not a dose for any one person.

How long does one retatrutide shot last?
About a week and more. Retatrutide is one peptide that works three hormone receptors: GLP-1 and GIP, the incretins (gut hormones released after a meal that help release insulin; GLP-1 also turns appetite down), and glucagon3. In the first human study, 45 healthy volunteers each got a single injection, at doses that rose from group to group, or a placebo, and were followed for weeks after it6. Its pattern in the blood supported once-weekly dosing, and the drop in body weight after that one shot persisted up to day 435.
The phase 1b trial in people with type 2 diabetes found its exposure rose in proportion to the dose and measured the half-life, the time for the level in the blood to fall by half, at about six days7. So the first shot is far from gone when the second one arrives, and each weekly dose adds to what is left. A drug with a six-day half-life takes roughly four to five half-lives, close to a month of weekly doses, to settle at a steady level, which is about when phase 3 took its first step up. The chart shows that build-up.
Try it
How Retatrutide builds up
An estimate from a half-life of about 6.3 days, one dose a week for four weeks. The shape of the level, not a measurement.

When does appetite change after the first shot?
Within the first weeks. In the phase 2 type 2 diabetes trial, people scored their appetite on a questionnaire, first at week 4. By then, every retatrutide group reported a weaker desire for something sweet than the placebo group. The groups are named by their target doses, 0.5 to 12 mg, but each began at 0.5, 2 or 4 mg11. By week 8 the 4, 8 and 12 mg groups reported a larger drop in overall appetite than placebo8.
The obesity trial asked people directly. In exit interviews with 40 participants, 31 of the 36 who had received retatrutide said their eating had changed within the trial's first eight weeks; those on 4 to 12 mg most often described smaller portions, eating less often, feeling hungry less often and full sooner9. The interviews took place at the end of the trial, so they rest on memory, and 13 of those 36 were on the lowest dose, 1 mg9.
Commonly reported: appetite dropping within the first week or two, often described as stronger than on tirzepatide; mild nausea or heavy fullness in the days after a shot; some tiredness; and the stomach effects returning briefly after each step-up.
When do side effects start on retatrutide?
Mostly in the climbing weeks. In the phase 2 obesity trial the stomach effects were dose-related and mostly mild to moderate3, and in its liver substudy they were transient and came primarily during dose escalation, with each step four weeks apart10.
The starting dose made a visible difference. In the obesity trial, the two arms in each pair below end on the same dose; what differs is how they began. These are the people in each arm who reported each event at any point in the trial, from its posted results4:
| Event | 4 mg target, 2 mg start (33) | 4 mg target, 4 mg start (33) | 8 mg target, 2 mg start (35) | 8 mg target, 4 mg start (35) | Placebo (70) |
|---|---|---|---|---|---|
| Nausea | 6 (18%) | 12 (36%) | 6 (17%) | 21 (60%) | 8 (11%) |
| Vomiting | 4 (12%) | 4 (12%) | 2 (6%) | 9 (26%) | 1 (1%) |
| Decreased appetite | 6 (18%) | 8 (24%) | 4 (11%) | 11 (31%) | 6 (9%) |

Reactions where the needle went in were not among the events reported by 5% or more of any group, the record's threshold for listing4. What helps with the queasy days is ordinary: smaller meals, eating slowly and stopping at the first sign of fullness, and steady sips of water through the day. PepVault's guide to retatrutide side effects has the rates for every dose. Get medical help the same day if you cannot keep fluids down or have severe belly pain that does not ease.
When does the scale start to move on retatrutide?
Within the first few months, though the published reports give no week 4 or week 8 figure: the phase 2 abstract and results record report weight at weeks 24 and 4834, and the phase 3 abstract at week 802. The earliest numbers come from the small trials. After the single shot in healthy volunteers, the drop in weight persisted up to day 435. In the 12-week phase 1b trial in people with type 2 diabetes, weight loss beyond placebo appeared to grow with the dose and reached about 9 kg (8.96) in the group of 12 that climbed through 3, 6, 9 and 12 mg7.
A gentler start cost little on the scale at the 8 mg target and some at the 4 mg target. In the phase 2 diabetes trial, these are the average weight losses at 36 weeks, by how each arm began11:
| Target dose | Weight lost, 2 mg start | Weight lost, 4 mg start |
|---|---|---|
| 4 mg | 7.9% | 10.4% |
| 8 mg | 16.8% | 16.3% |
Placebo lost 3.0% over the same 36 weeks11. From week 24 on, PepVault's guide to retatrutide week by week follows the weight.
How do you set up the first injection day?
Retatrutide has no label yet, so no official instructions exist for it. The closest approved model is tirzepatide's label (Zepbound), another once-weekly injection from the same maker, and the routine below follows its instructions12. What you need: the medicine as supplied, an alcohol swab, a sharps container and a way to record the shot.
- Pick a weekly day you can keep; the tirzepatide label allows any time of day, with or without meals.
- Wash your hands, then check the label and the liquid: the tirzepatide instructions say not to use medicine that is cloudy, discoloured or has particles.
- Choose the stomach, at least 2 inches (5 cm) from the belly button, or the thigh; use the back of the upper arm only when someone else gives the injection.
- Skip skin that is tender, bruised, scaly, hard or scarred, or has pits or lumps.
- Use a different spot from last week's; the same area is fine.
- Inject under the skin exactly as you were shown, and keep the needle in for the full count your device's instructions give.
- Record the date, the time and the site straight away.
- Over the next three days, note your appetite, any nausea and how much you ate.

PepVault's dose log keeps each shot with its date and time, and its reminders hold the weekly day. Log it in PepVault
Its injection-site sheet marks each site on a body map and pre-selects the next one in the rotation. Log it in PepVault
Tirzepatide's label also covers a missed week: take it as soon as possible within 4 days (96 hours), or after that skip it and take the next one on the usual day, and keep any change of injection day at least 3 days (72 hours) from the previous dose12. That is tirzepatide's rule; for retatrutide, the person supervising your treatment sets it.
Is retatrutide approved?
Not yet. Lilly plans to file with the FDA in the first quarter of 2027, and until a regulator approves it, the company states that it 'cannot be legally sold or marketed for human use'13.
Sources
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026. prnewswire.com
- Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PubMed 42814954
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
- ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Results record: participant flow and adverse events. clinicaltrials.gov
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022. PubMed 35985340
- ClinicalTrials.gov NCT03841630. A safety study of LY3437943 given as a single injection in healthy participants (phase 1; sponsor Eli Lilly and Company). clinicaltrials.gov
- Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. PubMed 36354040
- Kanu C et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: results of a phase 2 study. Diabetes Obes Metab. 2025. PubMed 40916752
- Goetz IA et al. Perceived benefits of treatment for obesity with retatrutide: a qualitative study of patients in a phase 2 clinical trial. Obes Pillars. 2025. PubMed 41216380
- Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PubMed 38858523
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. PubMed 37385280
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: prescribing information and instructions for use. DailyMed, label of Sept 2, 2026. dailymed.nlm.nih.gov
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. Press release, Sept 29, 2026. prnewswire.com
- Giblin K et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. PubMed 41090431
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.